Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears

The CEO of Spyre Therapeutics reported selling 15,000 shares for a total transaction value of about $740,000 on April 1, 2026. The transaction represented 2.33% of Cameron Turtle's directly held common stock holdings and reduced direct ownership to 627,540 common shares post-sale, as reported in the Form 4.